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Teresa Graell4, Andrea Larrañaga4, Manel Garcia4, Ana de la Arada4, Adrià Juanola2,3,5,
Alicia Coiduras4, Isabel Duaso4, Angel Casado4, Julian Martin4, Marta Ginès4,
Nuria Moreno4, Ana Gema Perez4, Laia Marti4, Mireia Bernat4, Montse Sola4,
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Primary care is the ideal setting for early identification of patients with non-alcoholic fatty
liver disease (NAFLD). NAFLD is a potentially progressive disease that may lead to cirrhosis
and liver cancer but is frequently underrecognized because subjects at risk are often not
evaluated. Controlled attenuation parameter (CAP) is a reliable method for non-invasive
quantification of liver fat. It has the advantage of simultaneous measurement of liver stiff-
ness (LS), an estimate of liver fibrosis. There is no information on CAP in subjects with risk
factors from primary care.
Aim
To investigate the prevalence of hepatic steatosis, as estimated by CAP, in subjects from
the community with metabolic risk factors and correlate findings with clinical and biochemi-
cal characteristics and LS.
Patients andmethods
Population-based study of 215 subjects with metabolic risk factors without known liver dis-
ease identified randomly from a primary care center. A control group of 80 subjects matched
by age and sex without metabolic risk factors was also studied. CAP and LS were assessed
using Fibroscan.
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Results
Subjects with risk factors had CAP values higher than those of control group (268±64 vs 243
±49dB/m,p<0.001). Prevalence of severe steatosis (CAP> 280dB/m) in subjects with risk
factors was 43%. In multivariate analysis, fatty liver index (FLI) and HOMA were indepen-
dent predictive factors of severe steatosis. There was a direct correlation between CAP and
FLI values (r = 0.52,p<0.001). Interestingly, prevalence of increased LS was 12.6% in the
risk group vs 0% in the control group (p<0.001). Increased LS occurred predominantly in
subjects with high CAP values.
Conclusions
A high proportion of subjects with metabolic risk factors seen in primary care have severe
steatosis. FLI could be used as a surrogate of CAP. Increased LS was found in a significant
proportion of subjects with risk factors but not in control subjects.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a major health problem worldwide because of its
high prevalence and its important long-term morbidity and mortality [1–5]. NAFLD affects
approximately 25% of the population worldwide and its incidence is growing rapidly because
of associated metabolic comorbidities, such as obesity, type-2 diabetes, hyperlipidemia, and
metabolic syndrome, the frequency of which is increasing at a very fast rate in most areas of
the world [1–3]. The presence of fat in the liver is associated with an increased risk of liver-
related morbidity and mortality through development of liver fibrosis and cirrhosis [6,7].
Moreover, patients with NAFLD have decreased survival compared to that of the general pop-
ulation due to cardiovascular complications, development of cirrhosis, and hepatic as well as
non-hepatic tumors [5,8,9].
The diagnosis of NAFLD relies on the demonstration of presence of hepatic steatosis in the
absence of secondary causes of fat accumulation such as significant alcohol consumption, use
of certain drugs or hereditary disorders [10,11]. The ideal setting for the diagnosis of NAFLD
is primary care because patients with risk factors for NAFLD are usually seen in the commu-
nity by primary physicians or nurse practitioners caring for their metabolic comorbidities. The
most commonly used method for diagnosis of hepatic steatosis in the community is liver ultra-
sonography because it is simple and widely available. However, liver ultrasonography has sev-
eral drawbacks, particularly limited sensitivity, difficulty in the morbidly obese, it is operator
dependent, only provides qualitative or semi-quantitative information about the amount of
fat, and is not useful for the detection of concomitant liver fibrosis [12]). In NAFLD, liver
fibrosis is important because its presence and severity predicts cirrhosis development and
long-term survival [9,13,14]. Other methods to estimate the amount of fat in the liver such as
proton magnetic spectroscopy or serum biomarkers, such as fatty liver index (FLI), SteatotestR,
and NAFLD fibrosis score, are generally not used in primary care [11,12].
Controlled attenuation parameter (CAP) is a system that measures the degree of ultrasound
attenuation by hepatic fat using a process based on vibration control transient elastography
[12]). A number of studies have demonstrated that CAP has high predictive accuracy of the
amount of fat in the liver, particularly in patients with NAFLD [15–17]. Therefore, CAP is cur-
rently considered a precise noninvasive method for assessment of hepatic fat. Moreover, CAP
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Innovación 2013-2016, project reference PI 12/
00330 and PI 16/00043 to PG. This grant was co
funded by the European Regional Develoment Fund
(ERDF) (FEDER). The study is also supported by
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has the additional advantage of the simultaneous evaluation of liver fibrosis by measurement
of liver stiffness (LS). [12]
Although there are numerous studies evaluating CAP in large series of patients with
NAFLD in tertiary hospitals, there is little information on the application of CAP in primary
care [18]. Particularly, there is no information on the use of CAP in assessment of hepatic stea-
tosis in subjects with metabolic risk factors in the community. In the current study, we used
CAP to assess the prevalence of hepatic steatosis in patients with metabolic risk factors identi-
fied randomly in a primary care center. The prevalence was compared to that of a control
group of subjects without metabolic risk factors. CAP values were correlated with clinical and
biochemical variables and also with LS.
Patients andmethods
Aims
The current study was aimed at investigating the prevalence of steatosis as assessed by CAP in
subjects from the community setting with metabolic risk factors but without known liver dis-
ease. Secondary objectives were: 1) to compare the prevalence of steatosis in subjects with met-
abolic risk factors with that of a control group of similar age and sex without metabolic risk
factors; and 2/ to correlate CAP values with clinical and biochemical characteristics as well as
LS.
Population and study protocol
This is a population-based, cross-sectional study that included 215 subjects with metabolic risk
factors but without know liver disease from the community setting. Subjects were recruited
from primary care center La Marina (Barcelona) and considered eligible for participation in
the study if they had at least one of the following metabolic risk factors, as reported elsewhere
[10]: 1/ obesity; 2/ type-2 diabetes mellitus; 3/ dyslipidemia; and 4/ metabolic syndrome, as
defined by presence of 3 or more of the following features: a/ waist circumference greater than
102 cm in men or 88 cm in women; b/ serum triglycerides150 mg/dL; c/ high-density lipo-
protein (HDL) cholesterol levels less than 40 mg/dL in men or less than 50 mg/dL in women;
d/ systolic blood pressure130 mmHg or diastolic blood pressure85 mmHg; and e/ fasting
plasma glucose110 mg/dL [19]. Subjects aged>18yr were identified using computer-gener-
ated random numbers from the patient registry that contains clinical information of citizens
assigned to the primary care center using metabolic risk factors shown above as keywords.
Patients with known diagnosis of liver disease were excluded. Other exclusion criteria were
active malignancy, severe chronic conditions, and admission in nursing homes. Eligible sub-
jects were then contacted by telephone by nurses or general practitioners from the primary
care center and invited to participate in the study. Subjects interested were invited to attend
the primary care center where a member of the research team explained carefully the objectives
of the investigation and the study protocol (Fig 1).
Patients who accepted signed a written informed consent. At the visit in the primary care
center, demographic and clinical data were collected from all participants. Weight, height,
waist circumference, and arterial pressure were measured. In addition, a blood sample was
taken to determine standard liver tests, lipid profile, serum ferritin, serum creatinine, glycated
hemoglobin, and fasting insulin levels. FLI was calculated using standard formula [20]. In all
subjects, CAP and LS were measured (see later). Subjects with LS>7kPa with the M probe or
>6.2 kPa with the XL probe, were referred to the Liver Unit of the Hospital Clı́nic of Barcelona
for hepatology consultation, which consisted of assessment of liver disease following a diag-
nostic protocol that included disease assessment and staging with liver tests, liver
CAP for hepatic steatosis in primary care
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ultrasonography, and liver biopsy in patients who accepted the procedure. Subjects with LS<7
or 6.2 with the M and XL probes, respectively, did not undergo further evaluation. These cut-
offs were selected on the basis of those used in previous studies [21–23]. A control group of
subjects matched (2:1) by sex and age (±5 years) with those of the study group, but without
metabolic risk factors was studied for comparison. Subjects for the control group were selected
among subjects attending consultations of primary care physicians. Of the 110 subjects who
accepted to participate, 30 subjects were subsequently excluded because metabolic risk factors
were identified during study assessment (n = 24) or alcohol risk consumption (n = 6). There-
fore, the control group consisted of 80 subjects. The protocol was approved by the Investiga-
tional Review Boards of the primary care center (Fundació Gol i Gorina) and Hospital Clı́nic i
Provincial of Barcelona.
Fig 1. The flow chart of the study.
https://doi.org/10.1371/journal.pone.0200656.g001
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CAP and liver stiffness measurements
CAP and LS measurements were performed by a single experienced operator (PR) using
Fibroscan system 502 touchR (Echosens, Paris). Either M or XL probes were used. The decision
to use the M or XL probes was made following the recommendation of the software of the sys-
tem. The principles of CAP have been reported in detail elsewhere [12,24]. Measurements
were always performed in the morning after overnight fast. CAP was computed only when LS
measurement was valid and with the same signals used to measure LS. The final CAP value
was the median of individual CAP values and was expressed in dB/m. In 3 of the 295 subjects
included (1%), LS could not be determined (body mass index–BMI- and waist circumference
in these patients were 43, 35, and 34 Kg/m2 and 140, 111, and 114 cm, respectively). The levels
of CAP used to define the presence and degree of steatosis were as follows: 1/<248dB/m, no
steatosis (S0); 2/ 248–268 dB/m, mild steatosis (S1); 3/>268 and280 dB/m, moderate steato-
sis (S2); and 4/>280 dB/m, severe steatosis (S3), as reported elsewhere [25]. Reliability of LS
measurements using specific criteria [26] showed that all measurements performed were either
reliable or very reliable (65% and 35%, respectively). No measurements had poor realiability
using these criteria.
Statistical analysis
Results for continuous variables were expressed as mean and standard deviation. Counts and
percentages were used for the description of the categorical variables. Comparisons between
two independent groups were made with the t-test (previously checking the hypothesis of vari-
ance homogeneity) for continuous normal-distributed variables. The Mann-Whitney U test
was carried out for continuous non-normal distributed variables in the case of 2 independent
groups. Comparison between variables of more than 2 groups was performed with ANOVA or
Kruskal-Wallis. Comparisons of categorical variables among groups were made with chi-
squared test or Fisher test if appropriate. Transaminase levels have been considered classically
as surrogate markers of steatosis. Therefore, the predictive accuracy of FLI in the diagnosis of
severe steatosis was compared with that of AST/ALT levels using AUROC curves.
Multivariate logistic regression models were performed to assess independent predictive
factors of steatosis, severe steatosis, and LS. The significance level for all statistical tests was set
at 0.05 two-tailed. All statistical analyses were performed using SPSS 20.0 software.
Results
Characteristics of the study population
Comparison of the demographic, clinical, and biochemical characteristics of subjects from the
risk group and control group is shown in Table 1.
As expected, due to the inclusion criteria, subjects with metabolic risk factors had marked
alteration of laboratory variables, such as glucose, triglycerides, HDL-cholesterol, glycated
hemoglobin, and HOMA, compared to control subjects without metabolic risk factors.
Prevalence of steatosis and factors associated with CAP values
The degree of steatosis and LS were related to the presence of metabolic risk factors. Subjects
with metabolic risk factors had significantly higher CAP and LS values compared to those of
control subjects (268±64 vs 243±49 dB/m and 4.9±2.7 vs 4.2±0.9 kPa, respectively; p<0.01 for
both) (Table 1). Moreover, the prevalence of steatosis was significantly higher in the risk factor
group compared to the control group, regardless the cutoff values of CAP used for steatosis
grading (Table 2).
CAP for hepatic steatosis in primary care
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Tables 3 to 5 show the comparison of baseline characteristics of subjects categorized into
different subgroups according to the cutoff levels of CAP of 248, 268, and 280 dB/m, which
allows a comparison of subjects with S0 vs S1-2-3 (Table 3), S0-1 vs S2-3 (Table 4), and S-0-1-2
vsS3 (Table 5).






Age (yr) 58 ± 12 62 ± 13 0.03
Male gender 35 (44%) 91 842%) 0.9
Tobacco consumption 45 (20%) 17 (19%) 0.7
Diabetes Mellitus 60 (28%) - <0.001
Dyslipidemia 150 (70%) - <0.001
Obesity (BMI30 Kg/m2) 113 (52%) - <0.001
Metabolic syndrome 98 (46%) - <0.001
Number of risk factors
1 86 (40%) - <0.001
2 66 (31%) -
3 63 (29%) -
BMI (Kg/m2) 31 ± 5 25 ± 2 <0.001
Waist circumference (cm) 104 ± 13 91 ± 10 <0.001
Glucose (mg/dL) 112 ± 40 89 ± 10 <0.001
Total cholesterol (mg/dL) 204 ± 44 198 ± 26 0.15
HDL- cholesterol (mg/dL) 49 ± 14 58 ± 16 <0.001
LDL-cholesterol(mg/dL) 129 ± 33 123± 24 <0.001
Triglycerides (mg/dL) 138 ± 83 83 ± 24 <0.001
ALT (IU/L) 26 ± 16 24 ± 11 0.16
GGT (IU/L) 34 ± 35 27 ± 40 0.16
Serum creatinine (mg/dL) 0.7 ± 0.1 0.7 ± 0.2 0.6
Albumin (g/L) 44 ± 2 43 ± 2 0.8
Ferritin (ng/mL) 125 ± 137 104 ± 91 0.21
Glycated hemoglobin (%) 6.2 ± 1 5.5 ± 0.3 <0.001
HOMA 5.7 ± 8.6 2.2 ± 1.4 <0.001
LS (kPa) 4.9 ± 2.7 4.2 ± 0.9 0.002
CAP (dB/m) 268 ± 64 243 ± 49 0.001
Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA,
Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter
https://doi.org/10.1371/journal.pone.0200656.t001







CAP> 248dB/m (S0 vs S1-2-3) 136 (63%) 37 (42%) 0.01
CAP> 268dB/m (S0-1 vs S2-3) 106 (49%) 27 (34%) 0.02
CAP> 280dB/m (S0-1-2 vs S-3) 93 (43%) 24 (30%) 0.045
Values are numbers of subjects and percentages (in brackets)
https://doi.org/10.1371/journal.pone.0200656.t002
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The degree of steatosis was associated with diabetes mellitus, obesity, metabolic syndrome,
greater BMI and waist circumference, and higher glucose, triglycerides, ALT, GGT, ferritin,
glycosylated hemoglobin, and HOMA levels, and lower HDL-cholesterol. Moreover, the
degree of steatosis was also associated with higher FLI values. There was a statistically signifi-
cant direct correlation between CAP and FLI values (r = 0.52, p<0.001) (Fig 2).
In multivariate analysis, factors independently associated with steatosis or severe steatosis
were FLI alone or in association with HOMA, respectively (Table 6).
If FLI was not included in the multivariate analysis, variables independently associated with
CAP>248 dB/m were triglycerides and BMI, and those associated with CAP>280 dB/m were
triglycerides, waist circumference, and glycated hemoglobin. The direct relationship between
CAP and FLI was also observed in the whole population of subjects included in the study, with
and without metabolic risk factors (r = 0.48, p<0.001).
Table 3. Comparison of baseline characteristics of subjects with risk factors for NAFLD categorized according to the presence (S1-2-3) or absence (S0) of steatosis




n = 79 n = 136
Age (yr) 63 ± 13 62 ± 12 0.7
Male gender 30 (38%) 61 (45%) 0.4
Tobacco consumption 12 (15%) 31 (23%) 0.4
Diabetes Mellitus 16 (20%) 44 (32%) 0.06
Dyslipidemia 53 (67%) 97 (71%) 0.54
Obesity (BMI30kg/m2) 30 (38%) 83 (61%) 0.002
Metabolic syndrome 28 (35%) 70 (51%) 0.02
Number of risk factors
1 14 (18%) 15 (11%) 0.03
2 29 (38%) 45 (34%)
>3 28 70 (51%)
BMI (Kg/m2) 29 ± 5 32 ± 5 <0.001
Waist circumference (cm) 100 ± 12 106 ± 12 <0.001
Glucose (mg/dL) 102 ± 35 118 ± 42 0.006
Total cholesterol (mg/dL) 203 ± 46 204 ± 43 0.9
HDL- cholesterol (mg/dL) 53 ± 17 47 ± 12 0.008
LDL-cholesterol(mg/dL) 129 ± 36 128 ± 31 0.9
Triglycerides (mg/dL) 113 ± 69 152 ± 87 0.001
ALT (IU/L) 22 ± 11 28 ± 17 0.002
GGT (IU/L) 29 ± 30 38 ± 38 0.08
Creatinine (mg/dL) 0.7 ± 0.3 0.7 ± 0.2 0.7
Albumin (g/L) 44 ± 2 44 ± 3 0.8
Ferritin (ng/mL) 111 ± 109 134 ± 151 0.2
Glycated hemoglobin (%) 5.9 ± 0.9 6.3 ± 1.1 0.01
HOMA 3.5 ± 2.8 7.0 ± 10.4 <0.001
FLI 52 ± 27 73 ± 21 <0.001
LS (kPa) 4.2 ± 1.1 5.3 ± 3.2 <0.001
CAP (dB/m) 204 ± 38 305 ± 43 <0.001
Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA,
Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter.
https://doi.org/10.1371/journal.pone.0200656.t003
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As shown in Fig 3, the predictive accuracy of FLI in the diagnosis of severe steatosis was sig-
nificantly better than that of AST or ALT.
The best cutoff value of FLI for the diagnosis of severe steatosis was of 96. Similar findings
were observed when the whole population of subjects, with and without risk factors, was con-
sidered or when analyzing moderate/severe steatosis instead of severe steatosis (data not
shown). It is important to emphasize that 84 of the 106 (79%) subjects with risk factors and
moderate or severe steatosis had normal AST and ALT values.
Liver stiffness measurement and relationship with CAP
Twenty-seven of the 215 subjects (12.6%) of the risk group had increased LS, as estimated by
values greater than 7kPa or 6.2 kPa, with the M and XL probes, respectively. By contrast, none
of the 80 subjects from the control group without metabolic risk factors had increased LS (x2 =
Table 4. Comparison of baseline characteristics of subjects with risk factors for NAFLD categorized according to the presence (S2-3) or absence (S0-1) of moderate-





n = 109 n = 106
Age (yr) 62 ± 13 63 ± 12 0.5
Male gender 42 (38%) 49 (46%) 0.27
Tobacco consumption 20 (18%) 23 (22%) 0.46
Diabetes Mellitus 20 (18%) 40 (38%) 0.002
Dyslipidemia 72 (66%) 78 (74%) 0.24
Obesity (BMI30kg/m2) 43 (40%) 70 (66%) <0.001
Metabolic syndrome 38 (35%) 60 (57%) 0.002
Number of risk factors
1 18 (17%) 11 (11%) 0.001
2 42 (40%) 32 (31%)
>3 38 (35%) 60 (56%)
BMI (Kg/m2) 29 ± 5 33 ± 5 <0.001
Waist circumference (cm) 100 ± 12 107 ± 12 <0.001
Glucose (mg/dL) 101 ± 31 124 ± 45 <0.001
Total cholesterol (mg/dL) 205 ± 44 202 ± 45 0.54
HDL- cholesterol (mg/dL) 52 ± 16 46 ± 11 <0.001
LDL-cholesterol(mg/dL) 129 ± 34 128 ± 32 0.79
Triglycerides (mg/dL) 119 ± 70 157 ± 91 0.001
ALT (IU/L) 23 ± 11 30 ± 18 0.001
GGT (IU/L) 28 ± 27 41 ± 42 0.009
Creatinine (mg/dL) 0.7 ± 0.2 0.8 ± 0.2 0.6
Albumin (g/L) 44 ± 25 44 ± 2.6 0.9
Ferritin (ng/mL) 108 ± 1.17 142 ± 154 0.08
Glycated hemoglobin (%) 5.9 ± 0.7 6.5 ± 1.2 <0.001
HOMA 3.4 ± 2.6 8.5 ± 11 <0.001
FLI 54 ± 26 77 ± 20 <0.001
LS (kPa) 4.3 ± 1.2 5.6 ± 3.6 0.001
CAP (dB/m) 218 ± 40 319 ± 38 <0.001
Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA,
Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter
https://doi.org/10.1371/journal.pone.0200656.t004
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11.1; p<0.001). If a higher cutoff of LS was considered (>8Kpa) the prevalence of increased LS
in the risk group was of 4% (9 of the 215 subjects). Factors associated with increased LS in uni-
variate analysis were diabetes mellitus, obesity, BMI, waist circumference, glucose, ALT, gly-
cated hemoglobin, HOMA, and CAP (Table 7)
In multivariate analysis, variables independently associated with increased LS were diabetes
mellitus, waist circumference, and ALT (Table 8).
Prevalence of increased LS was significantly greater in subjects with severe steatosis (S3)
than in those with mild/moderate (S1-2) or no steatosis (S0) (22% vs 5 and 6%, respectively
(Fig 4). Remarkably, in the control group without metabolic risk factors, none of the subjects
had increased LS regardless of CAP values (Fig 4).
Fig 5 shows the relationship between LS and CAP and LS and FLI in subjects with meta-
bolic risk.
Table 5. Comparison of baseline characteristics of subjects with risk factors for NAFLD categorized according to the presence (S3) or absence (S0-1-2) of severe





n = 122 n = 93
Age (yr) 62 ± 13 63 ± 12 0.5
Male gender 48 (39%) 43 (46%) 0.3
Tobacco consumption 24 (19%) 19 (21%) 0.63
Diabetes Mellitus 25 (21%) 35 (38%) 0.009
Dyslipidemia 83 (68%) 67 (72%) 0.55
Obesity (BMI30kg/m2) 49 (41%) 64 (69%) <0.001
Metabolic syndrome 46 (38%) 52 (56%) 0.009
Number of risk factors
1 21 (18%) 8 (9%) 0.003
2 44 (37%) 30 (33%)
>3 46 (38%) 52 (56%)
BMI (Kg/m2) 29 ± 5 33 ± 5 <0.001
Waist circumference (cm) 100 ± 11 109 ± 11 <0.001
Glucose (mg/dL) 103 ± 36 124 ± 43 <0.001
Total cholesterol (mg/dL) 207 ± 45 199 ± 43 0.18
HDL- cholesterol (mg/dL) 52 ± 16 45 ± 11 <0.001
LDL-cholesterol(mg/dL) 130 ± 34 126 ± 32 0.37
Triglycerides (mg/dL) 122 ± 69 159 ± 94 0.001
ALT (IU/L) 23 ± 12 30 ± 19 0.006
GGT (IU/L) 29 ± 28 41 ± 43 0.02
Creatinine (mg/dL) 0.7 ± 0.2 0.8 ± 0.2 0.6
Albumin (g/L) 44 ± 2 44 ± 2 0.9
Ferritin (ng/mL) 109 ± 114 146 ± 161 0.05
Glycated hemoglobin (%) 5.9 ± 0.9 6.4 ± 1.1 0.001
HOMA 3.7 ± 3.3 8.2 ± 12 0.001
FLI 56 ± 25 78 ± 20 <0.001
LS (kPa) 4.4 ± 1.2 5.6 ± 3.8 <0.001
CAP (dB/m) 224 ± 41 325 ± 36 <0.001
Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA,
Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter
https://doi.org/10.1371/journal.pone.0200656.t005
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The 27 patients with increased LS were referred to the hospital for hepatology consultation
and 22 accepted. In all 22 patients the diagnosis of NAFLD was confirmed by ultrasonography.
Mean LS and CAP values in these patients were 10.0±5.9kPa (range 6.6–31.6) and 323±67
dBm (range 170–400), respectively. Nine of the 22 patients (40%) underwent a liver biopsy. LS
values in patients in whom a liver biopsy was performed were 13.3±8.2 kPa (range 7–31.6).
Histological examination showed significant liver fibrosis in 3 (F2, F3 and F4) associated with
moderate steatosis, and steatosis without fibrosis in 6 patients (severe and moderate in one
patient each, and mild in the remaining 4 patients).
Fig 2. Correlation between CAP and FLI values in the 215 subjects with metabolic risk factors of NAFLD included
in the study.
https://doi.org/10.1371/journal.pone.0200656.g002
Table 6. Multivariate Logistic Regression analysis of variables associated with steatosis and severe steatosis.
Steatosis (CAP 248dB/m)
Independent Variable OR CI P value
FLI 1.032 1.019–1.046 <0.01
Severe steatosis (CAP 280dB/m)
Independent Variables
FLI 1.036 1.02–1.052 <0.001
HOMA 1.085 1.007–1.169 0.031
Variables included in the model for Steatosis: FLI, Triglycerides, BMI, Waist circumference, HDL-cholesterol, ALT,
Glycated Hb and HOMA.
Variables included in the Severe Steatosis model: FLI, Diabetes, BMI,Waist circumference, HDL-cholesterol, ALT,
Glycated Hb and HOMA
https://doi.org/10.1371/journal.pone.0200656.t006
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Discussion
The results of the current study show that a high proportion of subjects with metabolic risk
factors from the community, without known liver disease, have severe steatosis as indicated by
high values of CAP. The degree of steatosis did not correlate with transaminase levels but
showed good correlation with FLI. Increased LS, suggestive of liver fibrosis, was only found in
subject with metabolic risk factors and increased CAP values.
Epidemiological studies indicate that NAFLD affects more than 25% of the adult population
worldwide and is particularly common among subjects with metabolic risk factors [1–3].
Patients with NAFLD should be identified not only because they are at risk of developing liver
fibrosis subsequently leading to cirrhosis and hepatocellular carcinoma, but also because they
have increased mortality due to cardiovascular events [1–3]. Although hepatic steatosis with-
out inflammation has been classically considered a “benign” condition, without risk of pro-
gression, recent studies indicate that as much as one fourth of patients with simple steatosis
can progress to steatohepatits and fibrosis within a short period of time [27,28]. Most subjects
at risk for NAFLD are in the community setting and not in the hospital unless they develop
Fig 3. Predictive accuracy of FLI, AST and ALT, as assessed by AUROC curves, in the diagnosis of severe steatosis in the
group of patients with metabolic risk factors of NAFLD.
https://doi.org/10.1371/journal.pone.0200656.g003
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some acute complications. Therefore, identification should ideally be performed in primary
care. Interestingly, it has been reported that NAFLD is frequently underrecognized in the pri-
mary care setting and subjects with metabolic risk factors are not frequently evaluated for this
condition [29,30].
Along these lines, the results of the current study, in which CAP was used for evaluation of
hepatic steatosis, demonstrate that 43% of adults subjects with metabolic risk factors and previ-
ously unrecognized liver disease identified randomly from primary care have severe steatosis.
Previous studies have shown that other noninvasive methods to estimate hepatic steatosis,
including hepatic ultrasound or transaminase levels, lack sensitivity in the detection of hepatic
steatosis [12]. CAP is not a perfect method, but studies in which CAP values have been






Age 62 ± 12 65 ± 13 0.2
Male gender 76 (83%) 15 (16%) 0.15
Diabetes Mellitus 46 (24%) 14 (52%) 0.005
Dyslipidemia 135 (72%) 15 (56%) 0.12
Obesity (BMI30kg/m2) 94 (50%) 19 (73%) 0.03
Metabolic syndrome 83 (44%) 15 (56%) 0.3
BMI (Kg/m2) 30 ± 5 35 ± 6 <0.001
Waist circumference (cm) 102 ± 11 115 ± 13 <0.001
Glucose (mg/dL) 107 ± 34 146 ± 58 0.002
Total cholesterol (mg/dL) 206 ± 45 188 ± 36 0.05
HDL- cholesterol (mg/dL) 50 ± 15 46 ± 13 0.2
LDL-cholesterol(mg/dL) 130 ± 34 118 ± 28 0.1
Triglycerides (mg/dL) 134 ± 80 165 ± 97 0.065
ALT (IU/L) 25 ± 13 36 ± 24 0.02
GGT (IU/L) 31 ± 28 57 ± 69 0.06
Albumin (g/L) 44 ± 2 43 ± 3 0.6
Ferritin (ng/mL) 115 ± 109 194 ± 253 0.1
Glycated hemoglobin (%) 6 ± 0.9 6.8 ± 1.3 0.007
HOMA 4.7 ± 6.2 12.6 ± 16.61 0.03
FLI 63 ± 25 85 ± 18 <0.001
CAP (dB/m) 261 ± 59 316 ± 71 <0.001

>7 Kpa with M probe or>6.2 kPa with XL probe.
Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA,
Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter.
https://doi.org/10.1371/journal.pone.0200656.t007
Table 8. Multivariate logistic regression analysis of variables associated with increased liver stiffness in subjects
with risk factors for NAFLD.
VARIABLE OR CI P value
Diabetes Mellitus 4.8 1.7–13.4 0.002
Waist circumference 1.1 1.04–1.1 <0.001
ALT 1.03 1.003–1.057 0.03
Variables included in the model: BMI, waist circumference, ALT, Glycated Hb and HOMA, Diabetes mellitus, CAP,
FLI
https://doi.org/10.1371/journal.pone.0200656.t008
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compared with liver histology, show that the AUROC curves for severe steatosis (>66% of
hepatocytes) are greater than 0.8 [16]. Therefore, it is likely that the majority of subjects identi-
fied in the current study with high CAP values had severe steatosis. Unfortunately, histological
confirmation is not available because liver biopsy was only performed in a small number of
subjects who had increased LS. As expected from results of previous studies, CAP values corre-
lated strongly with metabolic factors, particularly diabetes mellitus, obesity, metabolic syn-
drome, BMI, waist circumference, glucose, LDL-cholesterol, triglycerides, ALT, glycated
hemoglobin, and HOMA [15–18].
Another interesting observation of the current study was the existence of a direct correla-
tion between CAP and FLI values. Remarkably, in multivariate analysis, FLI was an indepen-
dent predictive factor of steatosis and severe steatosis. This strong direct correlation found is
probably related to the fact that the four components of FLI (BMI, waist circumference, tri-
glycerides, and GGT) are strongly related to metabolic syndrome [20]. Our findings confirm
previous observations in subjects from the general population [18]. Altogether, these findings
suggest that FLI can be used as a surrogate marker to estimate hepatic steatosis in subjects in
the community setting if the determination of CAP is not available.
Our study also evaluated the relationship between CAP and LS. The correlation between
CAP values and LS was very weak, both in the group of subjects with metabolic risk factors
and in the overall population of subjects. In this context, it is important to remind that our
Fig 4. Prevalence of increased liver stiffness (>7kPa or>6.2kPa with the M and XL probes, respectively), in the group of subjects with risk factors for NAFLD
(grey bars) and control group (no bars because of 0% prevalence) categorized in 3 subgroups according to CAP values.
https://doi.org/10.1371/journal.pone.0200656.g004
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population was composed of subjects from the community setting in which, contrarily to that
of the hospital setting, the prevalence of increased LS is low. However, a closer look at individ-
ual values of CAP and LS showed that increased LS was almost exclusively observed in patients
with high CAP values indicative of severe steatosis. Of interest, none of the subjects from the
control group had increased LS despite the fact that some of them had relatively high CAP val-
ues, yet lower than those in the metabolic risk group. The number of subjects with histological
examination was relatively low. In some subjects, significant liver fibrosis was confirmed
(from F2 to F4), whereas in others there was only steatosis without significant liver fibrosis.
This lack of fibrosis in some subjects may be related to the fact that steatosis “per se” may
Fig 5. (upper panel) Relationship between liver stiffness and CAP values in patients with risk factors for NAFLD.
(lower panel) Relationship between liver stiffness and FLI values in patients with risk factors of NAFLD. Empty circles
represent patients with liver stiffness greater than 8 kPa.
https://doi.org/10.1371/journal.pone.0200656.g005
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increase LS values [31]. The possibility of a sampling error in liver biopsy also exists yet it is
difficult to prove. Recent studies have demonstrated that the presence of steatosis increases LS
and therefore the cut-off level for significant liver fibrosis in patients with NAFLD should be
around 9kPa, higher than that in other disease states such as viral hepatitis [23,32]. The rela-
tionship between LS and CAP values has been investigated in great detail in a recent study by
Karlas et al which analyzed a very large population of patients with different etiologies of
chronic liver disease and from different geographical areas [33]. Overall, the study showed that
CAP has a small impact on classification of patients with significant fibrosis according to LS.
In populations with low prevalence, consideration of CAP can improve slightly the already
high negative predictive value of LS in ruling out significant liver fibrosis. Moreover, the study
confirmed that the accuracy of LS for detecting significant liver fibrosis is limited, due to high
rate of false-positive values, particularly in patients with large CAP values [33]. As an example,
in our study 3 subjects who underwent a liver biopsy for LS> 14 kPa and who had CAP values
350 dB/m did not have fibrosis in the liver biopsy.
The findings of the current study also provide interesting information with respect to
potential screening strategies for liver fibrosis related to NAFLD in primary care [34,35]. Our
results support that screening should be focused in subjects with metabolic risk factors and
that subjects without metabolic risk factors should not be screened because of very low proba-
bility of significant liver fibrosis. In fact, none of the subjects without metabolic risk factors
included in the study had increased LS. Interestingly, a recent large population-based study
showed that the prevalence of LS>9.2kPa among subjects without risk factors was of only
0.4%, compared to 5.4% in subjects with risk factors [23].
The present study has several strengths: 1/ it is population-based; patients were randomly
selected from subjects attending a primary care center; 2/ both the M and XL probes of the
Fibroscan system were used; this allowed acquiring reliable measurements in the majority of
subjects included in the study despite a high proportion of obese patients; and 3/ a control
group of subjects without metabolic risk factors was evaluated for comparison. However, the
study has also some limitations that should be mentioned: 1/ liver histology should ideally
have been obtained in a higher proportion of patients to correlate histological findings with
CAP values; however, although this may be feasible in series of patients from hospital care, this
is unrealistic in the setting of primary care, where the acceptability of invasive procedures is
very low in relatively healthy populations; 2/ the study was performed in a single primary care
center of an urban area; therefore, results would require validation in other primary care cen-
ters, also from non-urban areas; and 3/ the sample size is relatively low and results should ide-
ally be validated in larger subject populations.
In conclusion, almost half of subjects with metabolic risk factors with unknown liver dis-
ease status seen in primary care have increased values of CAP, indicative of moderate-to-severe
steatosis. FLI could be used as a surrogate marker of CAP in primary care because of good cor-
relation between the two variables. Significant liver fibrosis was only found in subjects with
metabolic risk factors and associated high CAP values, yet the frequency of liver fibrosis found
was lower compared to that in previous studies.
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